Hizentra® Vials to be Discontinued

– All Hizentra® Patients to Transition to Prefilled Syringes

April 12, 2024

Hizentra® [immune globulin subcutaneous (human) 20% liquid] Vial SKUs

This is an important notification from CSL Behring regarding the availability and upcoming discontinuation of Hizentra vial SKUs. CSL Behring will discontinue all sizes of Hizentra vials in the US by end of September 2024. We are providing this advance notice so that all distribution customers, providers and patients are made aware.

Over the next several months appropriate vial patients should be transitioned to Hizentra prefilled syringes (PFS) and new Hizentra patients should be started on PFS. You will receive a final Hizentra vial discontinuation notification once all Hizentra vial inventory has been exhausted.

Please see below for your reference all Hizentra Product SKUs:

Discontinued Vial Product SKUs 9/30/24
Product SKU Description NDC Number
Hizentra 1 g/5 mL Vial 44206-0451-01
Hizentra 2 g/10 mL Vial 44206-0452-02
Hizentra 4 g/20 mL Vial 44206-0454-04
Hizentra 10 g/50 mL Vial 44206-0455-10
Currently Available Product PFS SKUs
Product SKU Description NDC Number
Hizentra 1 g/5 mL Pre-filled Syringe 44206-0456-21
Hizentra 2 g/10 mL Pre-filled Syringe 44206-0457-22
Hizentra 4 g/20 mL Pre-filled Syringe 44206-0458-24
Hizentra 10 g/50 mL Pre-filled Syringe 44206-0455-25

CSL Behring believes it is in the best interest of Hizentra patients to simplify their infusion process, offering them a simple, convenient, and ready-to-use option in Hizentra prefilled syringes that eliminates the need for a vial transfer. CSL Behring is committed to putting patients’ needs first, and to delivering innovative, life-saving medicines to patients.

Hizentra is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years and older, as well as for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.1

If you have additional questions, a variety of resources are available.

  1.  Contact your CSL Behring Associate Director Corporate Accounts
  2.  For any medical/clinical questions, contact CSL Behring’s Medical Information Team at (800) 504-5434.

1 Please see Important Safety Information and full Prescribing Information.